Is levorphanol a better option than methadone?
ConclusionUnlike methadone, levorphanol is a more potent NMDA antagonist, possesses a higher affinity for DOR and KOR, has a shorter plasma half‐life yet longer duration of action, has no CYP450 interactions or QTc prolongation risk, can be a viable option in the elderly, palliative care, and SCI patients, requires little to no need for co‐administration of adjuvant analgesics, and has potentially a lower risk of drug‐related Emergency Department visits compared to other opioids.
Source: Pain Medicine - Category: Anesthesiology Authors: Thien C. Pham, Jeffrey Fudin, Robert B. Raffa Tags: Commentary Source Type: research
More News: Anesthesiology | Chronic Pain | Drugs & Pharmacology | Emergency Medicine | Methadone | Pain | Pain Management | Palliative | Palliative Care | Science | Study